Kyrgyzstan has moved to expand its domestic drug manufacturing capacity with the signing of a memorandum for a planned USD 1 billion pharmaceutical industrial park, a project that would rank among the country's most ambitious attempts to reduce its heavy reliance on imported medicines.

A Full-Cycle Complex in Three Stages

The proposed park is described as a full-cycle pharmaceutical complex planned for a 20-hectare site. Development would take place in three stages over a period of six years. According to the source report, the park is expected to include a research center, drug-production facilities, a medical devices center, and a business incubator.

The project remains at an early stage. As the source notes, the proposed USD 1 billion pharmaceutical park is, for now, at the memorandum stage, and no completion or construction timeline beyond the six-year, three-stage plan has been publicly detailed.

Questions Surround the Private Partner

Little is publicly known about 21st Century Biomedicine, the company with which the National Investment Agency signed the memorandum. The source states that the company has little visible public profile and that no clear record of previous pharmaceutical projects appears in publicly available sources. Kyrgyz reports indicate that Bishkek-based MedPharm Consulting will provide organizational, technical, and legal support for the development.

The involvement of a partner without a documented track record in pharmaceuticals may attract scrutiny as the project moves from memorandum toward implementation.

A Market Dominated by Imports

The proposal comes against the backdrop of a pharmaceutical market in which domestic production plays a very small role. In November 2025, a Health Ministry official said that imports accounted for around 97% of medicines sold in the country, with domestic producers supplying about 3%. The National Investment Agency puts domestic production at around 4% of Kyrgyzstan's pharmaceutical needs.

According to the agency, if the park is completed, the project is expected to raise the country's pharmaceutical self-sufficiency to 25–30%. The proposed development is also expected to create 2,500–3,000 direct jobs and more than 10,000 indirect jobs.

The authorities are pursuing two parallel tracks: developing domestic production while also expanding infrastructure for storing and distributing medicines. In September, construction began in Bishkek on a state pharmaceutical warehouse and logistics complex for Kyrgyzpharmatsiya, the state enterprise responsible for centralized procurement of medicines and medical supplies for public healthcare institutions. The new facility is worth around $7.4 million and is intended to improve the storage and nationwide distribution of pharmaceuticals.

EAEU Standards as an Export Gateway

Drug production at the proposed industrial park is planned to comply with the Eurasian Economic Union's Good Manufacturing Practice standards. These standards set common requirements for pharmaceutical manufacturing and quality control across the EAEU's five member states: Armenia, Belarus, Kazakhstan, Kyrgyzstan, and Russia. Meeting those standards would be one requirement for exporting medicines within the union, making compliance a potential factor in the commercial viability of the planned facilities.

Growing Chinese Interest in the Sector

The memorandum is the latest development in a period of growing Chinese interest in Kyrgyzstan's pharmaceutical sector. In December 2024, the government approved an investment agreement for a Kyrgyz-Chinese pharmaceutical project led by Standard Pharm Group, with planned investment of more than USD 41 million. Chinese investors have since discussed further projects, including a pharmaceutical plant that would use locally grown medicinal herbs.

The convergence of foreign-backed initiatives and state-led efforts to raise self-sufficiency underscores how far Kyrgyzstan's domestic pharmaceutical industry currently sits from meeting national demand, with roughly 3–4% of medicines consumed in the country produced locally.

From Memorandum to Implementation

The signing represents a first formal step rather than a binding commitment, and the source material makes clear that the project's realization is not assured. The stated expectations, self-sufficiency of 25–30%, thousands of direct and indirect jobs, and EAEU-compliant manufacturing, all depend on the park being completed as envisioned.

What follows the memorandum stage is not specified in the source. No details on financing arrangements, construction start dates, or confirmation of the 21st Century Biomedicine partnership beyond the memorandum itself have been reported.

The development of the MedPharm Consulting support role, and any further clarification of the private partner's background and financing capacity, will likely shape perceptions of the project's prospects as more information becomes available.

Stay Ahead of Central Asia's Industrial Expansion with Real-Time Project Intelligence

Central Asia's industrial sector is expanding at a pace that leaves no room for guesswork. Every delayed project insight is a lost opportunity for suppliers, contractors, and investors alike.

That's why industry leaders rely on the Global Project Tracking (GPT) platform by Blackridge Research. It delivers verified, up-to-date intelligence on industrial projects across the Central Asia region, so you can identify prospects early, track competitors, and time your market entry with precision.

From drug plants and chemical facilities to manufacturing hubs and logistics corridors, the platform covers every stage of the project lifecycle in one unified dashboard.

• Upcoming Projects

• Tender Notices

• Contract Awards

• Projects Under Construction

• Completed Projects

Book a Free Demo today and see how the Global Project Tracking (GPT) platform by Blackridge Research can turn Central Asia's industrial pipeline into your competitive advantage.